Cerevel rises on starting mid-stage trials of schizophrenia therapy

Cerevel Therapeutics Holdings

01/08/2022 16:03

** Drug developer Cerevel Therapeutics Holdings Inc's shares
 CERE.O  rise 11% to $29.35
    ** Co starts two parallel mid-stage trials of its
experimental schizophrenia treatment, Emraclidine
    ** Schizophrenia is a mental disorder that causes people to
interpret reality abnormally
    ** Data for both trials is expected in H1 2024
    ** Says $531 mln in cash, cash equivalents and marketable
securities will support its operation till 2024  
    ** Despite session's gains, stock down ~2% 

 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))